I have some important news to announce. Last week I started on treatment for my hep C again, six years after my previous treatment failed. This time I was fortunate to qualify for the Early Access Program for Boceprevir treatment.
This treatment consists of 4 weeks of Pegylated Interferon and Ribavirin, which is the current Standard of Care in Australia, and at week 5 we add the Boceprevir tablets for a further 32 weeks.
Last Friday night, the 28th of October, I took my first Ribavirin tablets and my first ...